F5 Inc vs 10X Genomics Inc — how do they compare? F5 Inc trades at $415.62 (market cap $23.22B), while 10X Genomics Inc trades at $58.61 (market cap $7.64B). The key difference: F5 Inc is far larger — about 3× 10X Genomics Inc's market cap. Which is the better fit depends on your goals.
| FFIV | TXG | |
|---|---|---|
Market Cap | $23.22B | $7.64B |
Sector | Technology | Health |
52-Week High | $431.26 | $58.57 |
52-Week Low | $223.99 | $11.34 |
Enterprise Value | $21.86B | $7.17B |
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $400.23, down 3.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, and raised its fiscal outlook, driven by 19% product revenue growth. Fundamentals show robust profitability with a net income margin of 21.95% and consistent revenue growth, though valuation ratios like a P/E of 31.89 appear elevated. Analyst sentiment is mixed with a 40% buy rating.
The outlook is cautiously optimistic given earnings momentum and raised guidance, but risks include high valuation and competitive pressures. The consensus price target of $430.43 suggests modest upside potential from current levels, contingent on sustained execution in application security and hybrid cloud demand.
No Aura AI signal available yet.
Trailing returns across standard periods
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →